The tumor was pathophysiologically characterized as a WHO grade 2 oligodendroglioma with an IDH (isocitrate dehydrogenase) mutation, 1p19q codeletion, and MGMT (O6-methylguanine-DNA methyltransferase) gene promoter methylation. The gene discussed is MGMT; the disease is neoplasm.